Male breast cancer (BC) represents an individual subtype of BC, with therapeutic procedures based on female BC therapy results. The present study evaluated the parameters currently used for the characterization and therapy of male BC, and their association with disease-free (DFS) and overall survival (OS), aiming to obtain a comprehensive basis to improve the personalized care of male BC. A total of 196 patients from March 1970 to March 2018 (mean follow-up, 84.9 months) were profiled, using clinicopathological review, molecular assessment [BRCA1/2, DNA repair associated (BRCA1/2) status, immunohistochemistry, fluorescence hybridization and DNA flow cytometry] and Cox regression statistical analysis. The median age of patients was 66.5 years. At presentation, 39.2% of patients with invasive carcinomas were in anatomic stage (AS) I. Patients exhibited primarily invasive carcinomas of no special type, histological grade 2, estrogen receptor α-(ERα) and progesterone receptor (PR)-positive, receptor tyrosine kinase erbB-2-negative, high Ki-67, Luminal B-like and aneuploid tumors. A total of 13 of the 44 (29.5%) BRCA-evaluated patients exhibited BRCA2 mutations, significantly associated with family history (FH), bilaterality, high Ki-67 expression, absence of PR and Luminal B-like tumors. Bilaterality was associated with the occurrence of non-breast primary neoplasms (NBPN). The 5 and 10-year DFS rates, excluding patients with distant metastasis, NBPN and carcinomas (n=145) were 65.9 and 58.2%, respectively, and the 5 and 10-year OS rates were 77.5 and 59.2%, respectively. In the univariate analysis, Luminal B-like subtype, BRCA2 mutations, high Ki-67 expression, and AS II and III were significantly associated with shorter DFS and OS. In addition, age >70 years was associated with low OS. In the multivariate analysis, FH, AS II and III, and Luminal B-like subtypes were associated with poorer OS. In conclusion, the data from the present study emphasize the high incidence of BRCA2 mutation in male BC, and its association with FH, bilaterality, high Ki-67 expression, negative PR expression and Luminal B-like subtypes, and with shorter DFS and OS in univariate analysis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482395PMC
http://dx.doi.org/10.3892/mco.2019.1841DOI Listing

Publication Analysis

Top Keywords

luminal b-like
20
high ki-67
16
ki-67 expression
12
male breast
8
breast cancer
8
male association
8
invasive carcinomas
8
patients exhibited
8
brca2 mutations
8
bilaterality high
8

Similar Publications

Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.

Breast Cancer Res Treat

November 2024

Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.

Article Synopsis
  • The study investigates the role of CCND1 gene amplification in the prognosis of hormone receptor-positive breast cancer patients, particularly in the context of resistance to endocrine therapy.
  • A cohort of 894 breast cancer patients was analyzed, revealing that 12.9% had CCND1 amplification, predominantly in luminal B-like and HER2-positive tumor types.
  • The findings indicate that while CCND1 amplification is common in certain breast cancer subtypes, it does not show significant differences in disease-free survival or overall survival among HR-positive, HER2-negative patients.
View Article and Find Full Text PDF

JAK/STAT signaling maintains an intermediate cell population during prostate basal cell fate determination.

Nat Genet

December 2024

Key Laboratory of Multi-Cell Systems, Shanghai Key Laboratory of Molecular Andrology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.

Article Synopsis
  • Unipotent basal and luminal stem cells are essential for maintaining prostate health, with a newly identified intermediate population (Basal-B) emerging during inflammation or cancer.
  • Basal-B cells show increased organoid formation capabilities and are considered a temporary basal stem cell state influenced by androgen levels and JAK/STAT signaling.
  • The study highlights that inflammation promotes the transition of Basal-B cells to luminal cells, while inhibiting JAK/STAT signaling can lessen this transition and potentially impacts prostate disease development like neoplasia.
View Article and Find Full Text PDF

Background: Menopausal hormone therapy (MHT) is associated with an increased risk of postmenopausal breast cancer, predominantly the luminal A-like subtype. The impact of MHT on deaths from breast cancer subtypes is less understood. This study aimed to explore associations between MHT use and the incidence, mortality, and survival of intrinsic-like breast cancer subtypes.

View Article and Find Full Text PDF

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.

BMC Cancer

October 2024

Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21-23, Erlangen, 91054, Germany.

Background: Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the different molecular cancer subtypes. Therefore, we here evaluated the effect of physical activity on progression-free and overall survival (PFS, OS) in metastatic breast cancer, specifically looking at molecular subtypes.

Methods: International Physical Activity Questionnaire (IPAQ) questionnaires, filled out by patients enrolled in the prospective PRAEGNANT registry (NCT02338167; n = 1,270) were used to calculate metabolic equivalent task (MET) minutes, which were subsequently categorized into low (n = 138), moderate (n = 995) or high IPAQ categories (n = 137).

View Article and Find Full Text PDF

Background/aim: Breast cancer is a heterogeneous disease with many subtypes, and the association between these subtypes and exposure to environmental factors such as radiation remains controversial. Although the rat is used widely for research into human breast cancer, the heterogeneity and subtype definitions are unclear. Here, we leveraged an archive of rat mammary cancer samples and gene expression microarray data to classify tumors and examine their association with exposures.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!